STOCK TITAN

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of common stock of Tango Therapeutics, Inc. on a Schedule 13G. The holding represents 6.0% of Tango’s common stock.

The filing shows shared voting power over 9,740,098.80 shares and shared dispositive power over 9,740,206.80 shares, with an aggregate beneficial ownership of 9,742,402.80 shares. The securities are attributed to Goldman Sachs & Co. LLC as a broker-dealer and investment adviser subsidiary of The Goldman Sachs Group, Inc., which is reporting as a parent holding company. The Goldman Sachs reporting units disclaim beneficial ownership of certain client accounts and investment entities as described in the disclosure.

Positive

  • None.

Negative

  • None.
Aggregate beneficial ownership 9,742,402.80 shares Common stock of Tango Therapeutics reported by Goldman Sachs entities
Ownership percentage 6.0% Percent of Tango Therapeutics common stock class beneficially owned
Shared voting power 9,740,098.80 shares Shares of Tango Therapeutics over which Goldman Sachs reports shared voting power
Shared dispositive power 9,740,206.80 shares Shares of Tango Therapeutics over which Goldman Sachs reports shared dispositive power
CUSIP 87583X109 CUSIP number for Tango Therapeutics common stock, par value $0.001 per share
beneficially owned financial
"The securities being reported on by The Goldman Sachs Group, Inc. are owned, or may be deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 9,740,098.80"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 9,740,206.80"
parent holding company financial
"The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company"
investment adviser financial
"an investment adviser registered under Section 203 of the Investment Advisers Act of 1940"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

What percentage of TNGX does The Goldman Sachs Group, Inc. report owning on this Schedule 13G?

The Goldman Sachs Group, Inc. reports beneficial ownership of 6.0% of Tango Therapeutics, Inc. common stock. This percentage is based on an aggregate beneficial ownership of 9,742,402.80 shares as stated in the Schedule 13G.

How many TNGX shares does Goldman Sachs report as having shared voting power over?

Goldman Sachs reports shared voting power over 9,740,098.80 Tango Therapeutics shares. This means voting authority is held jointly rather than on a sole basis, and there is no sole voting power reported in this filing.

What is the aggregate number of TNGX shares beneficially owned by Goldman Sachs in this filing?

The filing shows an aggregate beneficial ownership of 9,742,402.80 shares of Tango Therapeutics common stock. This figure underpins the reported 6.0% ownership stake in the company’s outstanding common shares.

Does Goldman Sachs report sole dispositive power over TNGX shares in this Schedule 13G?

No. The filing shows sole dispositive power of 0.00 shares and shared dispositive power over 9,740,206.80 shares. Dispositive power refers to the authority to dispose of or direct the disposition of the securities.

Which Goldman Sachs entities are named as reporting persons for the TNGX Schedule 13G?

The reporting persons are The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. Goldman Sachs & Co. LLC is described as a broker or dealer and registered investment adviser, and is a subsidiary of The Goldman Sachs Group, Inc.

Does Goldman Sachs disclaim any beneficial ownership of TNGX shares in this filing?

Yes. The Goldman Sachs reporting units disclaim beneficial ownership of securities held in certain client accounts and investment entities where interests are held by persons other than the Goldman Sachs reporting units, as described in the Item 4 information exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





87583X109

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



THE GOLDMAN SACHS GROUP, INC.
Signature:Name: Sam Prashanth
Name/Title:Attorney-in-fact
Date:07/17/2026
GOLDMAN SACHS & CO. LLC
Signature:Name: Sam Prashanth
Name/Title:Attorney-in-fact
Date:07/17/2026
Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common stock, par value $0.001 per share, of TANGO THERAPEUTICS, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2026 THE GOLDMAN SACHS GROUP, INC. By:/s/ Sam Prashanth ---------------------------------------- Name: Sam Prashanth Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Sam Prashanth ---------------------------------------- Name: Sam Prashanth Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group. "EXHIBIT (99.3) ITEM 4 INFORMATION *In accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the ""Release""), this filing reflects the securities beneficially owned by certain operating units (collectively, the ""Goldman Sachs Reporting Units"") of The Goldman Sachs Group, Inc. and its subsidiaries and affiliates (collectively, ""GSG""). This filing does not reflect securities, if any, beneficially owned by any operating units of GSG whose ownership of securities is disaggregated from that of the Goldman Sachs Reporting Units in accordance with the Release. The Goldman Sachs Reporting Units disclaim beneficial ownership of the securities beneficially owned by (i) any client accounts with respect to which the Goldman Sachs Reporting Units or their employees have voting or investment discretion or both, or with respect to which there are limits on their voting or investment authority or both and (ii) certain investment entities of which the Goldman Sachs Reporting Units act as the general partner, managing general partner or other manager, to the extent interests in such entities are held by persons other than the Goldman Sachs Reporting Units."